VNRXNYSEIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
VOLITIONRX LTD
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.17−0.01 (-3.50%)
Close on Oct 19, 2026
- Market cap
- $1.59M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$8.7102 (−98.04%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
VOLITIONRX LTD grew revenue 86.3% to $2.46M over the twelve months to Jun 30, 2026. Free cash flow was -$19.58M.
Revenue
$2.46M
+86.3% vs. a year earlier
Operating income
-$19.42M
TTM Q2 2026
Free cash flow
-$19.58M
TTM Q2 2026
EPS, diluted
-$3.86
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.59M
- P/E ratio
- –
- Price to sales
- 0.65
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -1230.86%
Fundamentals
- Revenue
- $2.46M
- Net income
- -$25.64M
- EPS, diluted
- -$3.86
- Free cash flow
- -$19.58M
- Book value per share
- -$3.51
- Diluted shares
- 9M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$2.46M+86.3% YoY
Operating income
-$19.42M
Net income
-$25.64M
EPS, diluted
-$3.86
Free cash flow
-$19.58M
Reported periodTrailing twelve months